Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the target of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 429,000 shares, a decrease of 74.5% from the October 31st total of 1,680,000 shares. Currently, 2.0% of the company’s stock are sold short. Based on an average trading volume of 2,950,000 shares, the days-to-cover ratio is presently 0.1 days.

Cardio Diagnostics Price Performance

CDIO traded down $0.01 during midday trading on Wednesday, hitting $0.30. 1,375,391 shares of the company’s stock traded hands, compared to its average volume of 1,319,485. The stock’s fifty day simple moving average is $0.26 and its 200-day simple moving average is $0.43. Cardio Diagnostics has a one year low of $0.19 and a one year high of $3.56.

Wall Street Analyst Weigh In

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $2.00 price target on shares of Cardio Diagnostics in a research note on Tuesday, August 27th.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.